Abbisko Therapeutics Co. Ltd. announced that its self-developed next-generation CD73 inhibitor ABSK051 has obtained the clinical trial approval from the National Medical Products Administration of the People's Republic of China (" NMPA"). ABSK051 is about to enter the first-in-human ("FIH") Phase I clinical trial for the treatment of advanced solid tumors in China.

This is a voluntary announcement made by the Company. The Group cannot guarantee that ABSK051 will ultimately be successfully marketed.